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Abstract: Pancreatic and duodenal homeobox factor-1 (PDX-1) plays a crucial role in pancreas development, 
b-cell differentiation and in maintaining normal b-cell function by regulating several b-cell-related genes 
including insulin. PDX-1 has potency to induce insulin-producing cells in non b-cells in various tissues such 
as pancreas and liver and PDX-1-VP16 fusion protein more efficiently induces insulin-producing cells, 
especially in the presence of NeuroD or Ngn3. MafA is a recently isolated b-cell-specific transcription factor 
and functions as a potent transactivator for the insulin gene. MafA markedly enhances insulin gene promoter 
activity and ameliorates glucose tolerance in diabetic mice, especially in the presence of PDX-1 and NeuroD. 
Taken together, PDX-1 and MafA play a crucial role in inducing insulin-producing cells and could be a 
therapeutic target for diabetes.  
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INTRODUCTION 
 
Decrease of functioning pancreatic b-cell number 
and insufficient insulin biosynthesis and/or secretion are 
the hallmark of both type 1 and type 2 diabetes. Type 1 
diabetes results from insulin deficiency caused by the 
autoimmune destruction of insulin-producing b-cells and 
type 2 diabetes results from insufficient b-cell function as 
well as progression of insulin resistance. The number of 
patients  with  type  2  diabetes  is  markedly  increasing 
worldwide and nowadays type 2 diabetes is recognized 
as  the  most  prevalent  and  serious  metabolic  disease. 
Although pancreas and islet transplantation have exerted 
beneficial effects for diabetes, the limitation of available 
insulin-producing  cells  and  requirement  of  life-long 
immunosuppressive  therapy  are  the  main  obstacles. 
Indeed,  it  was  shown  that  islet  cell  transplantation, 
together  with  glucocorticoid-free  immunosuppression, 
results  in  excellent  glycemic  control  with  sustained 
freedom from exogenous insulin in type 1 diabetes
[1,2]. 
However,  the  scarcity  of  cadaveric  donors  to  treat 
millions of diabetic patients leads to a serious limitation 
to the widespread clinical application of this procedure. 
Therefore, it is very important to search for alternative 
sources to induce insulin-producing cells and to develop 
b-cell  substitutes  by  introducing  an  insulin-producing 
cells  in  non-b-cells.  In  addition,  because  b-cells  are 
destroyed by the b-cell-specific autoimmune response in 
type 1 diabetes, non-b-cells should be used to induce 
insulin production. It has been reported that various cells 
(tissues)  such  as  Embryonic  Stem  (ES)  cells,  liver, 
pancreas,  intestine  and  bone  marrow  could  induce 
insulin-producing cells after some particular treatment. 
Also,  many  attempts  have  been  done  to  replace  the 
function of b-cells by introducing various components of 
the insulin secretory machinery into various non-b-cells.  
 
Insulin gene therapy induces insulin production in 
non-b-cells  and  ameliorates  glucose  tolerance  in 
diabetic  model  animals:  It  has  been  considered  that 
insulin  gene  therapy  has  potential  for  treatment  of 
diabetes. The goal of insulin gene therapy is to restore 
and control insulin production and to reduce the elevated 
blood glucose levels to a normal range without causing 
hypoglycemia.  Indeed,  it  has  been  shown  that  direct 
insulin gene transfer in the liver induces hepatic insulin 
production and ameliorates the adverse effects of insulin 
deficiency in diabetic animals
[3-7]. Insulin gene therapy 
with adenovirus-mediated delivery system ameliorated 
glucose  tolerance  in  STZ-induced  diabetic  animals. 
Since  the  liver  possesses  glucose-sensing  system 
somewhat similar to that in b-cells including glucokinase 
and glucose transporter 2 (GLUT2), it was thought that 
the liver has the potential to respond to change in blood 
glucose levels. However such insulin gene therapy has 
been hampered by the absence of enzymes that process 
proinsulin  to  insulin  and  a  regulatory  system  that 
produces  and  secretes  insulin  in  response  to  glucose 
levels. Unlike b-cells, the liver lacks the prohormone 
convertases  PC2  and  PC3  for  insulin  processing. 
Recently  this  limitation  was  somehow  overcome  by 
converting the dibasic amino acid residues to a tetrabasic 
sequence to allow the proinsulin synthesized in the liver 
to be cleaved by furin
[8]. Also, although this limitation 
was  somehow  circumvented  by  the  development  of 
insulin single chain analog, the bioactivity of this insulin 
single chain was significantly reduced
[9]. Since b-cells 
contain  unique  features  that  allow  the  regulation  of Am. J. Biotechnol. Biochem., 1(2):54-63, 2005 
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insulin biosynthesis and secretion in response to glucose 
levels, it is not easy to reconstruct the regulated system in 
non-b-cells. The major hurdle for insulin gene therapy is 
the lack of highly regulated biosynthesis and secretion of 
insulin  in  non-b-cells.  In  order  to  obtain 
glucose-responsiveness  of  insulin  biosynthesis  and 
secretion,  liver-specific  promoters,  the  activities  of 
which are couples with glucose levels, have been used. 
The  promoters  of  L-type  Pyruvate  Kinase  (LPK), 
Phosphoenolpyruvate  Carboxykinase  (PEPCK), 
Glucose-6-Phosphatase  (G6Pase)  and  Insulin-like 
Growth  Factor  Binding  Protein  (IGFBP-1)  have been 
investigated  as  regulatory  elements  for 
glucose-responsive insulin production in the liver
[10-12]. 
This approach seemed to be effective, but the regulation 
was not perfect.  
  It was also shown that K cells, which are classified 
as an endocrine cell type in the gut, are good target for 
insulin  gene  therapy,  because  the  cells  have  glucose 
responsiveness and contain the necessary enzymes for 
proinsulin-insulin conversion. K cells function to secrete 
the hormone Gastric Inhibitory Peptide (GIP) in response 
to glucose level. In addition, K cells express glucokinase 
and glucose transporter 2 (GLUT2) and thereby sense the 
change  of  glucose  levels.  Indeed,  it  was  shown  that 
transgenic mice producing human proinsulin under the 
control  of  the  K  cell-specific  GIP  promoter  produce 
mature  bioactive  insulin  in  a  glucose  level-dependent 
manner and show normal glucose tolerance even after 
STZ  treatment
[6,7,13,14].  However,  since  K  cells  are 
present  in  the  crypts  of  the  gut,  viral  transduction 
efficiency  is  thought  to  be  very  low.  In  addition, 
intestinal  epithelial  cells normally undergo very rapid 
turnover. Therefore, it would be necessary to deliver the 
insulin  gene  into  K  cell  progenitor  cells  in  order  to 
achieve  long-term  insulin  production and an effective 
gene transfer methods for K cells should be developed to 
use K cells for insulin gene therapy. 
 
PDX-1  plays  a  crucial  role  in  pancreatic  b-cell 
differentiation and functions as a key transcription 
factor to induce insulin-producing cells: The pancreas 
is composed of exocrine (acini and ducts) and endocrine 
compartments  (islets  of  Langerhans  which  contain 
a-,b-,d-  and  PP-cells  that  produce  glucagon,  insulin, 
somatostatin and pancreatic polypeptide, respectively). 
During  the  pancreas  development,  differentiation  of 
endocrine and exocrine compartments from pancreatic 
buds  requires  the  coordinated  regulation  of  specific 
genes. This process can be envisioned as a hierarchy of 
transcription  factors that initiate and maintain various 
gene expression program, leading to definition of various 
pancreatic  cell  types  (Fig.  1).  In  inducing 
insulin-producing cells in some source cells (tissues), it 
would  be  a  useful  clue  to  mimic  and  reproduce  the 
alteration  of  various  pancreatic  transcription  factors 
found  during  normal  pancreas  development.  Also,  it 
would  be  useful  to  induce  pancreatic  key  (master) 
transcription  factor(s)  in  some  source  cells  (tissues) 
which  have  potency  to  induce  various  b-cell-related 
genes  including  insulin  (Fig.  2).  The  pancreatic  and 
duodenal homeobox factor-1 (PDX-1), a member of the 
homeodomain-containing  transcription  factor  family, 
also known as IDX-1/STF-1/IPF1
[15-17], is expressed in 
the pancreas and duodenum and plays a crucial role in 
pancreas  development
[18-25],  b-cell  differentiation
[26-37] 
and in maintaining normal b-cell function by regulating 
several  b-cell-related  genes
[38-44].  At  early  stages  of 
embryonic development, PDX-1 is initially expressed in 
the  gut  region  when  the  foregut  endoderm  becomes 
committed to common pancreatic precursor cells. During 
pancreas development, PDX-1 expression is maintained 
in precursor cells that coexpress several hormones and 
later  it  becomes  restricted  to  b-cells  (Fig.  1).  Mice 
homozygous for a targeted mutation in the PDX-1 gene 
are  apancreatic  and  develop  fatal  perinatal 
hyperglycemia
[18], suggesting the crucial role of PDX-1 
in  pancreas  development.  It  has  been  shown  that  the 
exogenous expression of PDX-1 induces the expression 
of  various  b-cell-specific
 
genes  including  insulin  in 
several cells (tissues) such as exocrine pancreas
[27, 31, 32] 
or  some  cell  populations  in  the  liver
[26,28,30,34-37]. 
Clinically,  mutations  in  PDX-1  are  known  to  cause 
Maturity-onset  Diabetes  of  the  Young  (MODY)
[45]. 
There are several other transcription factors important 
for  pancreas  development  and  b-cell  differentiation. 
Neurogenin3  (Ngn3),  a  bHLH  transcription  factor,  is 
involved  in  pancreas  development  and  endocrine 
differentiation
[46-52].  Transgenic  mice  overexpressing 
Ngn3  show  a  marked  increase  in  endocrine  cell 
formation,  indicating  that  Ngn3  induces  islet  cell 
precursors to differentiate (Fig. 1)
[47,48]. In contrast, mice 
with  targeted  disruption  of  Ngn3  have  no  endocrine 
cells
[49].  NeuroD,  a  member  of  the  basic 
Helix-Loop-Helix  (bHLH)  transcription  factor  family, 
also known as BETA2, is expressed in pancreatic and 
intestinal  endocrine  cells and neural tissue. NeuroD also  
plays an important role in pancreas development and in 
regulating  insulin  gene  transcription
[53-55].  Mice 
homozygous for the null mutation in NeuroD also have a 
striking  reduction  in  the  number  of  b-cells,  develop 
severe  diabetes  and  die  perinatally
[54].  Clinically, 
mutations in NeuroD cause Maturity-onset Diabetes of 
the Young (MODY)
[56]. Also, it has been reported that 
the insulin enhancer elements, E-box and A-box, play an 
important role in regulating cell-specific expression of 
the  insulin  gene
[57,58]  and  that  NeuroD  binding  to  the 
E-box as well as PDX-1 binding to the A-box is very 
important for insulin gene transcription (Fig. 3).  
It has been reported that various cells (tissues) such 
as Embryonic Stem (ES) cells, liver, pancreas, intestine 
and  bone  marrow  could  be  transdifferentiated  into 
insulin-producing cells. It was shown that ES cells have  Am. J. Biotechnol. Biochem., 1(2):54-63, 2005 
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Fig. 1: Pancreatic  transcription  factor  hierarchy  during 
the  pancreas  development  During  the  pancreas 
development,  differentiation  of  endocrine  and 
exocrine  compartments  from  pancreatic  buds 
requires  the  coordinated  regulation  of  specific 
genes.  This  process  can  be  envisioned  as  a 
hierarchy  of  transcription  factors  that  initiate  
and      maintain      various      gene    expression  
program,  leading  to  definition  of  various 
pancreatic cell types 
 
￿￿  
 
Fig. 2: Induction of insulin-producing cells by pancreatic 
key  transcription  factor  expression  Some 
pancreatic transcription factor (or together with 
some  other  pancreatic  transcription  factors) 
induces the expression of various b-cell-related
 
genes including insulin in several cells (tissues). 
Thus, it seems useful to induce some pancreatic 
key (master) transcription factors in some source 
cells  (tissues)  that  have  potency  to  induce  the 
expression of various b-cell-related
 
genes 
 
potency to differentiate into insulin-producing
[59-63], but 
the potential use of ES cells for the treatment of diabetes 
might not be appropriate from the ethical point of view. 
Therefore, adult tissue-derived stem (progenitor) cells 
have been also used to induce insulin-producing cells. 
Stem (progenitor) cells in pancreas have been shown to 
be differentiated into insulin-producing cells
[27,31,32,64-67]. 
Pancreatic ducts, acini and some populations in islets 
have  been  shown  to  have  potency to differentiate into  
 
 
Fig. 3: Key  transcription  factors  for  insulin  gene 
transcription  The  insulin  enhancer  elements, 
E-box  and  A-box,  play  an  important  role  in 
regulating cell-specific expression of the insulin 
gene. PDX-1 binding to the A-box and NeuroD 
binding to the E-box are very important for insulin 
gene transcription. Also, MafA, a recent identified 
b-cell-specific  transcription  factor,  binds  to  a 
conserved cis-regulatory element called RIPE3b 
in the insulin gene promoter region and functions 
as a potent transactivator for the insulin gene  
 
insulin-producing  cells.  The  pancreas  and  liver  arise 
from  adjacent  regions  of  the  endoderm  in  embryonic 
development and thus the liver has been thought to be 
one of the potential sources to induce insulin-producing 
cells
[26,30,34-37,55,68-71]. Intestinal epithelium-derived cells 
were  also  shown  to  induce  differentiation  into 
insulin-producing cells
[28,29]. Some populations in bone 
marrow  cells  were  also  shown  to  have  potency  to 
differentiate into insulin-producing cells
[33,72,73]. In such 
study, various pancreatic transcription factors have been 
used to induce insulin-producing cells in some source 
cells  (tissues).  Indeed,  it  was  reported  that  PDX-1 
induces the expression of various b-cell-specific
 
genes 
including  insulin  in  several  cells  (tissues)  such  as 
exocrine pancreas
[28,34,35] or some cell populations in the 
liver
[26,30,34-37]. These results suggest that it is useful to 
induce  pancreatic  key  (master)  transcription  factor(s) 
such  as  PDX-1  in  some  source cells (tissues) which 
have potency  to  induce  various b-cell-related genes 
including insulin.      
 
PDX-1-VP16  fusion  protein  efficiently  induces 
insulin-producing  cells  and  ameliorates  glucose 
tolerance,  especially  in  the  presence of NeuroD or 
Ngn3: While the pancreas and liver arise from adjacent 
regions of the endoderm in embryonic development, the 
liver has been thought to be a potential target for diabetes 
gene therapy
[26,30,34-37,55]. In addition, it has been shown 
recently that a modified form of XlHbox8, the Xenopus 
homolog of PDX-1, carrying the VP16 transcriptional 
activation domain from Herpes simplex virus, efficiently 
induces  insulin  gene  expression  in  the  liver  of  the 
tadpole
[71].  In  the  study,  transgenic  Xenopus  tadpoles 
carrying  the  contruct  transthyretin  promoter-Xlhbo 
x8-VP16 were prepared. Xlhbox8-VP16 was expressed 
only  in  the  liver  of  the  tadpoles.  In  the  transgenic 
tadpoles, the liver was converted to pancreas, containing 
both  exocrine  and  endocrine  cells,  while  liver Am. J. Biotechnol. Biochem., 1(2):54-63, 2005 
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differentiation  products  were  lost  from  the  regions 
converted to pancreas
[71]. Since the timing of events is 
such  that  the  liver  is  differentiating  by  the  time 
Xlhbox8-VP16  is  expressed,  they  consider  this  a 
transdifferentiation event rather than a reprogramming of 
embryonic  development
[71].  In  contrast,  conversion  of 
liver to pancreas was not observed by Xlhbox8 alone 
(without VP16).  
  Based  on  the  findings  in  tadpoles
[71],  effects  of 
PDX-VP16  fusion  protein  (PDX-1-VP16)  on 
differentiation  to  insulin-producing  cells  have  been 
examined in murine. Indeed, it was reported recently that 
PDX-1-VP16 rather than wild PDX-1 efficiently induces 
insulin-producing  cells  in  the  liver  and  ameliorates 
glucose  tolerance  in  diabetic  mice
[35-37].  Also,  it  was 
shown that PDX-1-VP16 efficiently induces insulin gene 
expression  in  the  liver  especially  in  the  presence  of 
NeuroD  or  Ngn3
[35].  Although  PDX-1-VP16  exerted 
only a little more obvious effect on the insulin promoter 
compared to wild type PDX-1, PDX-1-VP16, together 
with NeuroD (or Ngn3), dramatically increased insulin 
promoter activity. To examine the additional effect of 
VP16  on  PDX-1-mediated  induction  of  insulin  gene 
expression,  adenovirus  expressing  the  PDX-1-VP16 
fusion protein (Ad-PDX-1-VP16) was delivered into the 
cervical vein of C57BL6 mice. After Ad-PDX-1-VP16 
injection, both insulin 1 and 2 was detected in the liver, 
although insulin 1 was not detected by expression of wild 
type  PDX-1  (without  VP-16)
[35].  In  addition,  larger 
amounts  of  insulin  gene  expression  were  detected  by 
PDX-1-VP16  in  the  presence  of  NeuroD  (or  Ngn3). 
After treatment with Ad-PDX-1-VP16 plus Ad-NeuroD 
(or Ad-Ngn3), several insulin-positive cells and insulin 
secretory  granules  were  observed  in  the  liver  in 
immunostaining  and  electron  microscopy, 
respectively
[38].  Various  endocrine  pancreas-related 
factors  such  as  islet-type  glucokinase,  glucagon  and 
somatostatin  were  also  induced  after  treatment  with 
Ad-PDX-1-VP16  plus  Ad-NeuroD  (or  Ad-Ngn3). 
Furthermore,  in  STZ-induced  diabetic  mice,  blood 
glucose levels were decreased by PDX-1-VP16 alone, 
which was more pronounced compared to the effects of 
wild  type  PDX-1  and  were  further  decreased  by 
overexpression  of  PDX-1-VP16  plus  NeuroD  (or 
Ngn3)
[38].  The  marked  effects  of  PDX-1-VP16 
expression, together with NeuroD (or Ngn3), on insulin 
production  and  glucose  tolerance  indicate  that  such 
combination  is  useful  and  efficient  for  replacing  the 
reduced insulin biosynthesis found in diabetes and that 
PDX-1  requires  the  recruitment  of  coordinately 
functioning transcription factors or cofactors in order to 
fully exert its function (Fig. 2). In addition, these results 
suggest that synergistic activation of the E-box by bHLH 
transcription factors such as NeuroD or Ngn3 would be 
important  to  induce  insulin-producing  cells  in 
non-b-cells for the achievement of b-cell regeneration 
therapy in the future.   
  It  was  also  shown  recently  that  PDX-1-VP16 
expressing  hepatic  cells  converts  into  functional 
insulin-producing cells in the presence of high glucose
[36]. 
In  the  study,  they  generated  a  stably  transfected  rat 
hepatic  cell  line  named  WB-1  that  expresses 
PDX-1-VP16.  Expression  of  several  genes  related  to 
endocrine pancreas development and islet function was 
induced  by  PDX-1-VP16  in  the  liver  cells,  although 
some pancreatic transcription factors were missing. Also, 
theses cells failed to secrete insulin upon the glucose 
challenge. However, when WB-1 cells were transplanted 
into diabetic NOD-scid mice, almost all b-cell-related 
transcription  factors  were  induced  and  hyperglycemia 
was normalized
[36]. In addition, in vitro culture in high 
glucose  medium  was  sufficient  to  induce  completely 
maturation  of  WB-1  cells  into  functional 
insulin-producing  cells
[36].  These  results  suggest  that 
PDX-1-VP16  should  be  very  efficient  and  useful  for 
replacing  the  reduced  insulin  biosynthesis  and  for 
amelioration of glucose tolerance but that PDX-1-VP16 
alone  is  not  enough  to  induce  complete 
transdifferentiation to functional insulin-producing cells 
(Fig. 2).  
 
MafA, a recently isolated b-cell-specific
 transcription 
factor, functions as a potent transactivator for the 
insulin gene and in the presence of PDX-1, efficiently 
induces  insulin-producing  cells  and  markedly 
ameliorates glucose tolerance: It was previously shown 
that an unidentified b-cell-specific nuclear factor binds 
to a conserved cis-regulatory element called RIPE3b1 in 
the insulin gene enhancer region and is likely to function 
as  an  important  transactivator  for  the  insulin gene
[74]. 
Recently,  this  important  transactivator  for  the  insulin 
gene  was  identified  as  MafA,  a  basic-leucine  zipper 
transcription  factor  (Fig.  3)
[75-77].  The  C1/RIPE3b1 
activator from mouse bTC-3 cell nuclear extracts was 
purified  by  DNA  affinity  chromatography  and 
two-dimensional  gel  electrophoresis
[75].  C1/RIPE3b1 
binding  activity  was  found  in  the  roughly  46-kDa 
fraction at pH 7.0 and pH 4.5. MafA was detected in the 
C1/RIPE3b1  binding  complex  by  using  MafA 
peptide-specific antisera. In addition, MafA was shown 
to bind within the enhancer region of the endogenous 
insulin  gene  in  bTC-3  cells  in  the  chromatin 
immunoprecipitation  assay
[75].  These  results  strongly 
suggest  that  MafA  is  the b-cell-enriched component of  
the  RIPE3b1  activator.  MafA  controls  b-cell-specific 
expression of the insulin gene through a cis-regulatory 
element  called  RIPE3b1  and  functions  as  a  potent 
transactivator for the insulin gene
[75-80]. During pancreas 
development, MafA expression is first detected at the 
beginning of the principal phase of insulin-producing cell 
production
[78] while other important transcription factors 
such as PDX-1 and NeuroD are expressed from the early 
stage  of  pancreas  development  (Fig.  1).  In  addition, Am. J. Biotechnol. Biochem., 1(2):54-63, 2005 
 
￿ 58 
while both PDX-1 and NeuroD are expressed in various 
cell  types  in  islets,  MafA  is  the  only  b-cell-specific
 
transactivator for the insulin gene. Thus, the potency of 
MafA  as  an  insulin  gene  activator,  together
  with  its 
unique expression in b-cells, raises the likelihood
 that 
MafA  is  a  principal  factor  of  b-cell  formation
  and 
function. Also, it is likely that MafA is a useful factor to 
generate insulin-producing cells.  
  It  was  shown  recently  that  MafA,  together  with 
PDX-1  and  NeuroD,  efficiently  induces  insulin  gene 
expression in the liver
[79]. In HepG2 cells, basal insulin 
promoter activity was increased by MafA alone which 
was  much  more  significant  after  overexpression  of 
PDX-1 or NeuroD alone. Furthermore, MafA, together 
with PDX-1 plus NeuroD, drastically increased insulin 
promoter  activity
[79].  These  results  clearly  show  that 
MafA, PDX-1 and NeuroD exert strong synergistic effect 
on insulin promoter activity. Large amounts of insulin 1 
and 2 mRNA and insulin content were clearly observed 
in  the  liver  after  the  triple  infection  (Ad-MafA, 
Ad-PDX-1, plus Ad-NeuroD). Also, in immunostaining 
for  insulin,  many  insulin-positive  cells  were  clearly 
observed  in  the  liver  after  the  triple  infection
[79].  In 
STZ-induced diabetic mice, serum insulin levels were 
markedly  increased  after  the  triple  infection. 
Furthermore, in the diabetic mice, blood glucose levels 
were decreased by MafA plus PDX-1 (or NeuroD)
[79], 
although no such effect was observed after infection of 
Ad-MafA alone. Furthermore, blood glucose levels were 
dramatically decreased by the triple infection (Ad-MafA, 
Ad-PDX-1 and Ad-NeuroD). Theses results suggest a 
crucial role of MafA as a novel therapeutic target for 
diabetes and imply that such combination should be very 
efficient  and  useful  for  replacing  the  reduced  insulin 
biosynthesis found in diabetes (Fig. 2).  
 
Chronic  hyperglycemia  reduces  expression  and/or 
DNA  binding  activities  of  PDX-1  and  MafA  by 
provoking oxidative stress, leading to suppression of 
insulin biosynthesis and secretion found in diabetes: 
Chronic  hyperglycemia  is  a  cause  of  impairment  of 
insulin biosynthesis and secretion; once hyperglycemia 
becomes apparent, b-cell function gradually deteriorates 
and insulin resistance aggravates. This process is called 
“b-cell  glucose  toxicity”
[74,81-84].  In  the  diabetic  state, 
hyperglycemia  per  se  and  subsequent  production  of 
reactive oxygen species decrease insulin gene expression 
and secretion
[85-99]. It was previously shown that loss of 
insulin  gene  expression  is  accompanied  by  decreased 
expression and/or DNA binding activity of two important 
pancreatic  transcription  factors,  PDX-1
[82,85,87-91]  and 
RIPE3b1  activation  (which  was  recently  identified  as 
MafA)
[74,81,97]. After chronic exposure to a high glucose 
concentration, expression and/or DNA binding activity 
of PDX-1 and MafA are reduced (Fig. 4).  
 
￿￿  
 
Fig. 4: Role  of  PDX-1  and  MafA  in  b-cell  glucose 
toxicity￿ Chronic  hyperglycemia  suppresses 
insulin biosynthesis and secretion by provoking 
oxidative  stress,  accompanied  by  reduction  of 
expression  and/or  DNA  binding  activities  of 
PDX-1 and MafA. It is likely that the alteration of 
these  two  transcription  factors  leads  to 
suppression of insulin biosynthesis and thus plays 
a crucial role in b-cell glucose toxicity   
 
  Under diabetic conditions, Reactive Oxygen Species 
(ROS)  are  increased  in  pancreatic  b-cells  and  are 
involved  in  “b-cell  glucose  toxicity”  found  in 
diabetes
[85-99].  There  are  several  sources  of  ROS 
productions in cells such as the electron transport chain 
in mitochondria
[94] and the non-enzymatic glycosylation 
reaction
[85]. It was shown that when b-cell-derived HIT 
cells  or  rat  isolated  islets  were  exposed  to  oxidative 
stress,  insulin  gene  promoter  activity  and  mRNA 
expression  were  suppressed
[85,87-91].  Also,  the 
DNA-binding  activity  of PDX-1 is rather sensitive to 
oxidative  stress;  when  HIT  cells  or  rat  isolated islets 
were exposed to oxidative stress, PDX-1 binding to the 
insulin gene was markedly reduced. Also, it was shown 
that the decrease of insulin gene expression after chronic 
exposure to high glucose concentration is prevented by 
treatment  with  antioxidants
[87,88,97].  Furthermore, 
reduction of expression and/or DNA binding activities of 
PDX-1 and MafA by chronic exposure to high glucose 
was prevented by an antioxidant treatment. These results 
suggest  that  chronic hyperglycemia suppresses insulin 
biosynthesis and secretion by provoking oxidative stress, 
accompanied  by  reduction  of expression and/or DNA 
binding activity of two important pancreatic transcription 
factors, PDX-1 and MafA. Therefore, we assume that the 
alteration of these two transcription factors explains, at 
least in part, the suppression of insulin biosynthesis and 
secretion and thus play a role in “b-cell glucose toxicity” 
found in diabetes (Fig. 4).  
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CONCLUSIONS 
 
Pancreatic  transcription  factor  PDX-1  plays  a 
crucial  role  in  pancreas  development,  b-cell 
differentiation and in maintaining normal b-cell function 
by  regulating  several  b-cell-related  genes  including 
insulin.  MafA  is  a  recently  isolated  b-cell-specific 
transcription  factor  and  functions  as  a  potent 
transactivator  for  the  insulin  gene.  In  inducing 
insulin-producing cells in some source cells (tissues), it 
would  be  a  useful  clue  to  mimic  and  reproduce  the 
alteration  of  various  pancreatic  transcription  factors 
found  during  normal  pancreas  development.  Also,  it 
would  be  useful  to  induce  pancreatic  key  (master) 
transcription  factor(s)  in  some  source  cells  (tissues) 
which  have  potency  to  induce  various  b-cell-related 
genes including insulin. Induction of such transcription 
factors induces insulin-producing cells in some source 
cells  (tissues)  and  combination  of  such  transcription 
factors  is  very  efficient  and  useful  for  replacing  the 
reduced biosynthesis found in diabetes. Also, these two 
transcription factors PDX-1 and MafA play a crucial role 
in insulin gene transcription and in maintaining normal 
b-cell   function.   Under   diabetic   conditions, however, 
chronic hyperglycemia reduces expression and/or DNA 
binding  activities  of  PDX-1  and  MafA  by  provoking 
oxidative stress, which leads to suppression of insulin 
biosynthesis and secretion and thus plays a role in “b-cell 
glucose toxicity” found in diabetes. So far many studies 
have been performed to overexpress such transcription 
factors using adenovirus, but it would be very difficult to 
apply  the  adenovirus-mediated  approach  to  clinical 
medicine.  Some new strategies would be necessary to 
safely  overexpress  such  transcription  factors.  Protein 
Transduction Domains (PTDs) such as the small PTD 
from  the  TAT  protein  of  Human  Immunodeficiency 
Virus (HIV-1), the VP22 protein of Herpes simplex virus 
and  the  third  ￿-helix  of  the  homeodomain  of 
Antennapedia,  a  Drosophila  transcription  factor,  are 
known  to  allow  various  proteins  and  peptides  to  be 
efficiently  delivered  into  cells  through  the  plasma 
membrane and thus there has been increasing interest in 
their potential usefulness for the delivery of bioactive 
proteins and peptides into cells
[31,52,100-102]. Thus, it would 
be  promising  to  induce  pancreatic  key  (master) 
transcription factor(s) in some source cells (tissues) by 
using protein delivery system. 
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